NO2905338T3 - - Google Patents

Info

Publication number
NO2905338T3
NO2905338T3 NO14198318A NO14198318A NO2905338T3 NO 2905338 T3 NO2905338 T3 NO 2905338T3 NO 14198318 A NO14198318 A NO 14198318A NO 14198318 A NO14198318 A NO 14198318A NO 2905338 T3 NO2905338 T3 NO 2905338T3
Authority
NO
Norway
Application number
NO14198318A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2905338T3 publication Critical patent/NO2905338T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Position Input By Displaying (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
NO14198318A 2010-06-22 2011-06-22 NO2905338T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35731410P 2010-06-22 2010-06-22
US35731710P 2010-06-22 2010-06-22
EP11728508.0A EP2480675B1 (en) 2010-06-22 2011-06-22 Mice expressing a light chain with human lambda variable and mouse constant regions

Publications (1)

Publication Number Publication Date
NO2905338T3 true NO2905338T3 (pl) 2017-12-30

Family

ID=44509861

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14198318A NO2905338T3 (pl) 2010-06-22 2011-06-22

Country Status (30)

Country Link
US (22) US9035128B2 (pl)
EP (7) EP2568049B1 (pl)
JP (17) JP5988969B2 (pl)
KR (16) KR102211911B1 (pl)
CN (4) CN104342455B (pl)
AU (1) AU2011271046B2 (pl)
BR (3) BR112012032991B1 (pl)
CA (2) CA2803864C (pl)
CY (5) CY1117537T1 (pl)
DK (5) DK2480676T3 (pl)
ES (5) ES2575223T3 (pl)
HR (5) HRP20160794T1 (pl)
HU (5) HUE036597T2 (pl)
IL (12) IL313063A (pl)
LT (4) LT2905338T (pl)
ME (5) ME02444B (pl)
MX (6) MX347318B (pl)
MY (6) MY165287A (pl)
NO (1) NO2905338T3 (pl)
NZ (6) NZ627119A (pl)
PL (5) PL2480675T3 (pl)
PT (5) PT3034608T (pl)
RS (5) RS56589B1 (pl)
RU (3) RU2590594C2 (pl)
SG (4) SG186390A1 (pl)
SI (5) SI2905338T1 (pl)
SM (5) SMT201700506T1 (pl)
TR (1) TR201905992T4 (pl)
WO (2) WO2011163311A1 (pl)
ZA (5) ZA201300062B (pl)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
AU2009298458B2 (en) 2008-09-30 2015-10-08 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
JP5827127B2 (ja) 2008-12-18 2015-12-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用
US9445581B2 (en) * 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
DK3622815T3 (da) 2009-07-08 2023-06-26 Kymab Ltd Gnavermodeller og terapeutiske molekyler
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
ES2984483T3 (es) 2010-03-31 2024-10-29 Ablexis Llc Ingeniería genética de ratones para la producción de anticuerpos quiméricos
PT3034608T (pt) 2010-06-22 2019-05-28 Regeneron Pharma Ratinhos expressando uma cadeia leve híbrida de imunoglobulina com uma região variável humana
CN103025884B (zh) 2010-07-26 2015-11-25 特里安尼公司 转基因动物和使用方法
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
SMT201700023T1 (it) 2010-08-02 2017-03-08 Regeneron Pharma Topi che producono proteine leganti vl
HUE047278T2 (hu) 2011-08-05 2020-04-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
BR112014006394A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
EP2758534B1 (en) 2011-09-19 2020-04-29 Kymab Limited Animals, repertoires & methods for the production of human antibodies
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SG10201605675WA (en) * 2011-12-20 2016-09-29 Regeneron Pharma Humanized light chain mice
EP2825036B1 (en) 2012-03-16 2018-05-02 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
WO2013138681A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
EP3539374A1 (en) 2012-03-16 2019-09-18 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
SG11201405059XA (en) 2012-03-28 2014-09-26 Kymab Ltd Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
MY178882A (en) 2013-02-20 2020-10-21 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
EP4545567A3 (en) * 2013-03-13 2025-08-13 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
EP3841876A1 (en) 2013-03-14 2021-06-30 Erasmus University Medical Center Rotterdam Transgenic mouse for antibody production
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
RU2019121863A (ru) * 2013-09-18 2019-08-29 Регенерон Фармасьютикалз, Инк. Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения
AU2014330922A1 (en) 2013-10-01 2016-03-03 Kymab Limited Animal models and therapeutic molecules
TW201532513A (zh) * 2014-01-10 2015-09-01 Alfur Fu-Hsin Hung 能產生比小鼠ＩgＥ量高出許多的人源化ＩgＥ之基因轉殖動物
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
AU2015231025A1 (en) * 2014-03-21 2016-09-15 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
PE20170441A1 (es) 2014-06-06 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
JP2017529841A (ja) 2014-09-19 2017-10-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． キメラ抗原受容体
JP2017531642A (ja) 2014-10-03 2017-10-26 マサチューセッツ インスティテュート オブ テクノロジー エボラ糖タンパク質に結合する抗体およびその使用
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
WO2016097865A1 (en) 2014-12-19 2016-06-23 Regenesance B.V. Antibodies that bind human c6 and uses thereof
JP6180663B2 (ja) 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
EP3254035B1 (de) 2015-02-05 2019-01-30 Basf Se Solarkraftwerk mit einem ersten wärmeträgerkreislauf und einem zweiten wärmeträgerkreislauf
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
DK3303396T5 (da) 2015-05-29 2024-10-07 Bristol Myers Squibb Co Antistoffer mod ox40 og anvendelser deraf
CN107922500A (zh) 2015-06-29 2018-04-17 洛克菲勒大学 具有增强的激动剂活性的抗cd40抗体
CN105274116B (zh) * 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 一种制备人源化抗体的核酸分子及其应用
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
EP4414484A3 (en) 2016-02-04 2025-01-15 Trianni, Inc. Enhanced production of immunoglobulins
ES2985566T3 (es) 2016-03-04 2024-11-06 Univ Rockefeller Anticuerpos contra CD40 con actividad agonista mejorada
EP3423494A1 (en) 2016-03-04 2019-01-09 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
MX392069B (es) 2016-05-09 2025-03-21 Bristol Myers Squibb Co Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
CN113831407B (zh) 2016-05-20 2024-06-11 瑞泽恩制药公司 用于使用多个引导rna来破坏免疫耐受性的方法
KR102483193B1 (ko) 2016-06-03 2023-01-04 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
US20170371963A1 (en) * 2016-06-27 2017-12-28 Facebook, Inc. Systems and methods for identifying matching content
CN109757103B (zh) 2016-07-14 2024-01-02 百时美施贵宝公司 针对tim3的抗体及其用途
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
MX2019004371A (es) 2016-10-13 2019-11-18 Massachusetts Inst Technology Anticuerpos que se unen a la proteina de envoltura del virus zika y usos de los mismos.
EP3533867A4 (en) 2016-10-31 2020-07-22 National University Corporation Tottori University NON-HUMAN ANIMAL PRODUCING HUMAN ANTIBODIES AND PROCESS FOR THE PREPARATION OF HUMAN ANTIBODIES USING IT
SG10201913483XA (en) * 2016-11-04 2020-03-30 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain locus
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
HUE060608T2 (hu) 2017-12-05 2023-03-28 Regeneron Pharma Genetikailag módosított immunglobulin lambda könnyûlánccal rendelkezõ egerek és azok alkalmazása
EP3737700A1 (en) 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
EP3768715A1 (en) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
EP3772927B1 (en) 2018-03-24 2025-01-15 Regeneron Pharmaceuticals, Inc. Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
IL314733A (en) 2018-03-26 2024-10-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
JP7269963B2 (ja) * 2018-06-08 2023-05-09 クリスタル バイオサイエンス インコーポレイテッド 同じ軽鎖ｉを有する多様な抗体を産生するためのトランスジェニック動物
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
CN112969929B (zh) 2018-10-26 2024-06-21 日本汽车能源株式会社 电池控制装置
CN113316590B (zh) 2018-11-16 2025-02-28 百时美施贵宝公司 抗nkg2a抗体及其用途
CN113396162B (zh) 2019-01-22 2024-08-16 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
BR112021016173A2 (pt) 2019-02-22 2021-11-03 Regeneron Pharma Roedor geneticamente modificado, métodos de produção de um roedor geneticamente modificado e de produção de um anticorpo anti-nav1.7, célula ou tecido isolado de roedor, linhagem celular imortalizada, embrião de roedor, construto de ácido nucleico de direcionamento, e, hibridoma
MX2021014893A (es) * 2019-06-05 2022-03-11 Regeneron Pharma Animales no humanos que tienen un repertorio de cadena ligera lambda limitado expresado a partir del locus kappa y usos de estos.
DK3993623T3 (da) * 2019-07-01 2025-05-26 Zoetis Services Llc Transgene gnavere og fremgangsmåder til anvendelse deraf
US20220409732A1 (en) 2019-12-02 2022-12-29 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
WO2021261620A1 (ko) * 2020-06-25 2021-12-30 주식회사 휴맵 이형접합성 형질전환 동물
US20220090060A1 (en) 2020-09-11 2022-03-24 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
CN116848254B (zh) 2020-12-16 2026-03-17 瑞泽恩制药公司 表达人源化Fcα受体的小鼠
CA3165366A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
IL303865A (en) 2020-12-23 2023-08-01 Regeneron Pharma Methods for obtaining antibodies that bind transmembrane proteins and cells that produce them
WO2023199655A1 (ja) 2022-04-13 2023-10-19 日本精工株式会社 軸受装置の状態の検出方法、検出装置、およびプログラム
USD999969S1 (en) * 2022-04-29 2023-09-26 Shenzhen Intellirocks Tech. Co., Ltd. Lamp
EP4658687A1 (en) 2023-01-31 2025-12-10 University of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2024229461A2 (en) 2023-05-04 2024-11-07 Novasenta, Inc. Anti-cd161 antibodies and methods of use thereof
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026035843A2 (en) 2024-08-06 2026-02-12 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
CA2722378C (en) * 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
GB9823930D0 (en) * 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
RU2262511C2 (ru) * 2000-05-18 2005-10-20 Джапан Тобакко, Инк. Человеческое моноклональное антитело против ailim, костимулирующей молекулы передачи сигнала, и его фармацевтическое применение
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) * 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
GB0031284D0 (en) * 2000-12-21 2001-01-31 Ks Biomedix Ltd High affinity antibodies
CN1789416B (zh) * 2001-05-11 2011-11-16 协和发酵麒麟株式会社 含人抗体λ轻链基因的人类人工染色体
GB0115256D0 (en) * 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP2319301B1 (en) 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human Ig lambda light chain genes
US20030217171A1 (en) 2002-05-17 2003-11-20 Von Stuermer Wolfgang R. Self-replicating and self-installing software apparatus
ES2473596T3 (es) 2003-07-15 2014-07-07 Therapeutic Human Polyclonals, Inc. Loci de inmunoglobulina humanizada
CN1605628A (zh) * 2003-09-03 2005-04-13 中国疾病预防控制中心病毒病预防控制所 Cho细胞生产的人源抗甲肝病毒基因工程抗体
CA2575402A1 (en) * 2004-08-05 2006-02-09 Genentech, Inc. Humanized anti-cmet antagonists
ES2463476T3 (es) 2004-10-19 2014-05-28 Regeneron Pharmaceuticals, Inc. Método para generar un ratón homocigótico para una modificación genética
DE602005026571D1 (de) * 2004-12-29 2011-04-07 Yuhan Corp Tumornekrosefaktor-alpha spezifische humanisierte antikörper
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
JP2010501165A (ja) * 2006-08-22 2010-01-21 ジーツー インフラメイション プロプライエタリー リミテッド 抗体の作製方法
MY149079A (en) 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
US7864492B2 (en) 2006-10-31 2011-01-04 Siemens Industry, Inc. Systems and methods for arc fault detection
DE102007045897A1 (de) 2007-09-26 2009-04-09 Carl Zeiss Microimaging Gmbh Verfahren zur mikroskopischen dreidimensionalen Abbildung einer Probe
US8012714B2 (en) * 2008-04-14 2011-09-06 Innovative Targeting Solutions, Inc. Sequence diversity generation in immunoglobulins
EP2669298A3 (en) * 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
AU2009298458B2 (en) * 2008-09-30 2015-10-08 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
JP5827127B2 (ja) * 2008-12-18 2015-12-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用
DK3622815T3 (da) * 2009-07-08 2023-06-26 Kymab Ltd Gnavermodeller og terapeutiske molekyler
SMT202600080T1 (it) * 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
CN103228130B (zh) 2010-06-17 2016-03-16 科马布有限公司 动物模型及治疗分子
PT3034608T (pt) * 2010-06-22 2019-05-28 Regeneron Pharma Ratinhos expressando uma cadeia leve híbrida de imunoglobulina com uma região variável humana

Also Published As

Publication number Publication date
IL300712B1 (en) 2024-07-01
JP5988969B2 (ja) 2016-09-07
RU2724736C2 (ru) 2020-06-25
US20120073004A1 (en) 2012-03-22
WO2011163311A1 (en) 2011-12-29
ES2721749T3 (es) 2019-08-05
HK1168384A1 (zh) 2012-12-28
SMT201700506T1 (it) 2018-01-11
HUE029692T2 (en) 2017-03-28
US20150351371A1 (en) 2015-12-10
JP2020128440A (ja) 2020-08-27
RS55037B1 (sr) 2016-12-30
JP2021061863A (ja) 2021-04-22
US20150246977A1 (en) 2015-09-03
PT3034608T (pt) 2019-05-28
SMT201600229B (pl) 2016-08-31
JP2018023403A (ja) 2018-02-15
JP2020062061A (ja) 2020-04-23
KR20210013376A (ko) 2021-02-03
LT2905338T (lt) 2017-12-27
PL2480675T3 (pl) 2017-03-31
PT2568049T (pt) 2016-07-11
US9206261B2 (en) 2015-12-08
KR101970944B1 (ko) 2019-04-23
BR112012032991A8 (pt) 2020-09-29
US9035128B2 (en) 2015-05-19
EP2905338A1 (en) 2015-08-12
KR20180135996A (ko) 2018-12-21
ES2575223T3 (es) 2016-06-27
IL264634B (en) 2019-09-26
JP6243384B2 (ja) 2017-12-06
CN103068993A (zh) 2013-04-24
US20150320023A1 (en) 2015-11-12
PL3034608T3 (pl) 2019-08-30
US9206262B2 (en) 2015-12-08
IL255179A0 (en) 2017-12-31
JP2016010415A (ja) 2016-01-21
US20160057979A1 (en) 2016-03-03
HUE030285T2 (en) 2017-05-29
ZA201300062B (en) 2014-09-25
MX2012015300A (es) 2013-05-01
MY157477A (en) 2016-06-15
US9066502B2 (en) 2015-06-30
ME02440B (me) 2016-09-20
SMT201900241T1 (it) 2019-05-10
SI2568049T1 (sl) 2016-10-28
CA2804311A1 (en) 2011-12-29
RU2016119423A3 (pl) 2019-11-19
JP2025027148A (ja) 2025-02-26
US9334333B2 (en) 2016-05-10
HRP20190807T1 (hr) 2019-08-23
CY1119478T1 (el) 2018-03-07
MX2022002117A (es) 2022-03-17
KR102211911B1 (ko) 2021-02-05
BR112012032991B1 (pt) 2021-08-10
CN104404050B (zh) 2018-06-08
AU2011271043A8 (en) 2016-01-21
SG10201504324UA (en) 2015-07-30
SG186391A1 (en) 2013-01-30
JP2018201527A (ja) 2018-12-27
CN103068994B (zh) 2016-01-20
US20150089680A1 (en) 2015-03-26
KR20210134424A (ko) 2021-11-09
ZA201300063B (en) 2014-09-25
US20150246976A1 (en) 2015-09-03
PL2480676T3 (pl) 2016-10-31
JP6963542B2 (ja) 2021-11-10
JP2013531501A (ja) 2013-08-08
US20120070861A1 (en) 2012-03-22
HK1170766A1 (zh) 2013-03-08
ME03386B (me) 2020-01-20
US20130326647A1 (en) 2013-12-05
US9150662B2 (en) 2015-10-06
PT2480675T (pt) 2016-07-11
KR20200143511A (ko) 2020-12-23
ZA201506598B (en) 2017-03-29
RS58736B1 (sr) 2019-06-28
PL2905338T3 (pl) 2018-01-31
US20200239837A1 (en) 2020-07-30
KR102118565B1 (ko) 2020-06-03
AU2011271043A9 (en) 2015-10-01
KR101975884B1 (ko) 2019-05-10
LT3034608T (lt) 2019-05-27
US20150173331A1 (en) 2015-06-25
ME02444B (me) 2016-09-20
MX2012015298A (es) 2013-05-01
US9206263B2 (en) 2015-12-08
US9226484B2 (en) 2016-01-05
MY195217A (en) 2023-01-11
US9540452B2 (en) 2017-01-10
IL223720A (en) 2017-05-29
US10266803B2 (en) 2019-04-23
US20180064078A1 (en) 2018-03-08
US20170107484A1 (en) 2017-04-20
JP2016010417A (ja) 2016-01-21
US9394373B2 (en) 2016-07-19
US20190153384A1 (en) 2019-05-23
CA2804311C (en) 2017-09-12
CY1118126T1 (el) 2017-06-28
MX336344B (es) 2016-01-15
JP6073441B2 (ja) 2017-02-01
CY1122877T1 (el) 2021-05-05
US20150173332A1 (en) 2015-06-25
CY1117692T1 (el) 2017-05-17
US20130323790A1 (en) 2013-12-05
CN104342455B (zh) 2017-05-31
IL269078B (en) 2021-05-31
IL282872B (en) 2022-04-01
MX347322B (es) 2017-04-21
IL269078A (en) 2019-11-28
IL313063A (en) 2024-07-01
IL247386A (en) 2017-07-31
RU2601297C2 (ru) 2016-10-27
PL2568049T3 (pl) 2017-03-31
EP2568049A1 (en) 2013-03-13
JP2017006152A (ja) 2017-01-12
AU2011271046B2 (en) 2015-10-01
SG186390A1 (en) 2013-01-30
SI2480675T1 (sl) 2016-08-31
KR101934852B1 (ko) 2019-01-04
US9029628B2 (en) 2015-05-12
US20150176002A1 (en) 2015-06-25
IL259965B (en) 2019-02-28
AU2011271043A1 (en) 2013-01-31
KR20130027555A (ko) 2013-03-15
BR112012033248A2 (pt) 2017-11-28
CN103068994A (zh) 2013-04-24
LT2480675T (lt) 2016-10-10
CN104342455A (zh) 2015-02-11
DK2480675T3 (en) 2016-08-01
AU2011271043B2 (en) 2015-10-01
DK2480676T3 (en) 2016-06-20
KR102320944B1 (ko) 2021-11-04
SI3034608T1 (sl) 2019-06-28
AU2011271046A1 (en) 2013-01-31
CY1117537T1 (el) 2017-04-26
CN103068993B (zh) 2016-01-06
HUE029691T2 (en) 2017-03-28
CN104404050A (zh) 2015-03-11
KR20130121814A (ko) 2013-11-06
LT2568049T (lt) 2016-10-10
KR102059909B1 (ko) 2019-12-27
EP3034608A1 (en) 2016-06-22
EP2480676A1 (en) 2012-08-01
HUE036597T2 (hu) 2018-07-30
SI2480676T1 (sl) 2016-10-28
EP3034608B1 (en) 2019-01-30
KR20180135997A (ko) 2018-12-21
HUE044001T2 (hu) 2019-09-30
KR102001430B1 (ko) 2019-07-18
BR122020013427B1 (pt) 2021-08-03
EP2905338B1 (en) 2017-08-02
HK1183321A1 (en) 2013-12-20
JP6545773B2 (ja) 2019-07-17
RS56589B1 (sr) 2018-02-28
DK3034608T3 (da) 2019-05-06
BR112012032991A2 (pt) 2015-10-06
EP2480675A1 (en) 2012-08-01
JP2013532974A (ja) 2013-08-22
MY165287A (en) 2018-03-21
IL291301B2 (en) 2023-07-01
EP2905338B8 (en) 2018-01-24
JP2022066449A (ja) 2022-04-28
IL244450A (en) 2017-11-30
NZ605751A (en) 2014-10-31
JP2019033765A (ja) 2019-03-07
DK2568049T3 (en) 2016-08-01
IL291301B1 (en) 2023-03-01
HK1226766A1 (en) 2017-10-06
HRP20160794T1 (hr) 2016-08-12
US9006511B2 (en) 2015-04-14
ME02902B (me) 2018-04-20
DK2905338T3 (da) 2017-11-06
NZ707198A (en) 2016-04-29
CA2803864C (en) 2017-05-16
RU2013102596A (ru) 2014-07-27
KR20200064166A (ko) 2020-06-05
KR102266097B1 (ko) 2021-06-18
PT2905338T (pt) 2017-11-10
KR20190014576A (ko) 2019-02-12
RU2016119423A (ru) 2018-11-07
KR20210073609A (ko) 2021-06-18
PT2480676E (pt) 2016-06-09
EP2480676B1 (en) 2016-04-06
IL244450A0 (en) 2016-04-21
EP3205726A1 (en) 2017-08-16
SI2905338T1 (sl) 2017-12-29
ES2570131T3 (es) 2016-05-17
JP7236409B2 (ja) 2023-03-09
US9844212B2 (en) 2017-12-19
NZ626979A (en) 2015-05-29
ES2646052T3 (es) 2017-12-11
ZA201404601B (en) 2016-02-24
SG10201504568YA (en) 2015-07-30
SMT201600212B (it) 2016-08-31
KR20190073584A (ko) 2019-06-26
EP3456832A1 (en) 2019-03-20
IL255179B (en) 2018-06-28
MY194456A (en) 2022-11-30
IL300712B2 (en) 2024-11-01
ZA201404600B (en) 2015-09-30
KR20190049932A (ko) 2019-05-09
RS55042B1 (sr) 2016-12-30
IL291301A (en) 2022-05-01
IL223719A (en) 2016-10-31
MY195214A (en) 2023-01-11
MY195212A (en) 2023-01-11
KR20230036157A (ko) 2023-03-14
MX348942B (es) 2017-07-04
US9399683B2 (en) 2016-07-26
US9163092B2 (en) 2015-10-20
US20190203171A1 (en) 2019-07-04
JP2026066390A (ja) 2026-04-16
ES2576928T3 (es) 2016-07-12
US20140137275A1 (en) 2014-05-15
MX347318B (es) 2017-04-21
JP6341972B2 (ja) 2018-06-13
KR101945352B1 (ko) 2019-02-07
HRP20160865T1 (hr) 2016-10-07
SMT201600213B (it) 2016-08-31
NZ707200A (en) 2016-04-29
US9850462B2 (en) 2017-12-26
WO2011163314A1 (en) 2011-12-29
KR101991234B1 (ko) 2019-06-20
KR102193823B1 (ko) 2020-12-22
KR20190014578A (ko) 2019-02-12
HRP20160497T1 (hr) 2016-07-15
JP2023133554A (ja) 2023-09-22
RU2590594C2 (ru) 2016-07-10
JP2018201528A (ja) 2018-12-27
US20170258059A1 (en) 2017-09-14
IL300712A (en) 2023-04-01
HRP20171666T1 (hr) 2017-12-15
NZ627119A (en) 2015-05-29
KR102506001B1 (ko) 2023-03-07
KR102462042B1 (ko) 2022-11-03
IL259965A (en) 2018-07-31
IL282872A (en) 2021-06-30
EP2480675B1 (en) 2016-04-06
JP2017012204A (ja) 2017-01-19
US20160060359A1 (en) 2016-03-03
US20240327785A1 (en) 2024-10-03
ME02442B (me) 2016-09-20
KR20190142436A (ko) 2019-12-26
US9012717B2 (en) 2015-04-21
CA2803864A1 (en) 2011-12-29
TR201905992T4 (tr) 2019-05-21
NZ605758A (en) 2014-08-29
EP2568049B1 (en) 2016-04-13
JP6009441B2 (ja) 2016-10-19
RU2013102595A (ru) 2014-07-27
KR20220150430A (ko) 2022-11-10
RS54891B1 (sr) 2016-10-31

Similar Documents

Publication Publication Date Title
BR112013008959A2 (pl)
BR112012028408A2 (pl)
BR112012029986A2 (pl)
BR112012027808A2 (pl)
BR112012024897A2 (pl)
BR112012026492A2 (pl)
BR112012031500A2 (pl)
BR112012025307A2 (pl)
BR112012017960A2 (pl)
BR112012026946A2 (pl)
BR112012025482A2 (pl)
BR112013006400A2 (pl)
BR112012031826A2 (pl)
BR112012025577A2 (pl)
BR112012023249A2 (pl)
BR112012028186A2 (pl)
BR112012027015A2 (pl)
BR112012025308A2 (pl)
BR112012027945A2 (pl)
BR112013010949A2 (pl)
BR112012024872A2 (pl)
BR112012023265A2 (pl)
BR112012026403A2 (pl)
BR112013003284A2 (pl)
BR112013002646A2 (pl)